Tempus AI Raises 2025 Sales Guidance for the Second Time, Driven by Genomics Business Growth and New Product Developments.

Tempus AI has raised its 2025 sales guidance to $1.26 billion, up from $1.25 billion, driven by strong Q2 performance and growing demand for its Genomics business. The company reported a 89.6% YoY increase in revenues to $314.6 million and a 158.3% increase in gross profit to $195 million. Exact Sciences and Guardant Health also reported strong Q2 results, with Exact Sciences raising its 2025 revenue guidance to $3.13-$3.17 billion and Guardant Health raising its full-year 2025 revenue guidance to $915-$925 million.

Tempus AI (NASDAQ:TEM) has significantly boosted its 2025 sales guidance to $1.26 billion, up from $1.25 billion, following robust Q2 performance and surging demand for its Genomics business. The company reported an 89.6% year-over-year (YoY) increase in revenues to $314.6 million, with gross profit jumping 158.3% to $195 million [1].

Tempus AI's Q2 results highlight accelerating commercial momentum, significant margin expansion, and ongoing progress leveraging AI and data partnerships. The genomics and data services businesses both showed strong growth, with genomics revenue climbing 115.3% and data services revenue increasing 35.7% [1]. The company also announced a $750 million convertible notes offering, enhancing its financial flexibility for future investments in AI and diagnostics [1].

In a similar vein, Exact Sciences (EXAS) reported Q2 2025 earnings that exceeded expectations. The company narrowed its net loss by 92.5% to $1.19 million and raised its full-year revenue and EBITDA guidance amid 16% revenue growth. The Screening and Precision Oncology segments drove growth, reflecting strong market adoption of diagnostic tests [2]. Exact Sciences raised its 2025 revenue guidance to $3.13-$3.17 billion [2].

Guardant Health also reported strong Q2 results, raising its full-year 2025 revenue guidance to $915-$925 million. The company's precision oncology and liquid biopsy tests continue to perform well, with growing demand in the market [3].

These positive earnings reports from Tempus AI, Exact Sciences, and Guardant Health suggest a strong outlook for the genomics and diagnostics sector. Investors should watch for continued volume growth in genomics testing, further progress on AI product launches, and successful regulatory reimbursement for newer assays such as liquid biopsy.

References:
[1] https://www.nasdaq.com/articles/tempus-ai-tem-q2-revenue-surges-90
[2] https://www.ainvest.com/news/exact-sciences-2025-q2-earnings-narrowed-losses-raised-guidance-2508/
[3] https://www.guardanthealth.com/news/guardant-health-reports-q2-2025-results-and-raises-2025-revenue-guidance/